论文部分内容阅读
目的:观察多西紫杉醇(TXT)联合卡培他滨(CAP)方案与联合顺铂(DDP)方案治疗蒽环类耐药晚期乳腺癌的近期疗效和不良反应。方法:89例患者随机分组,接受TXT+CAP(TC)或TXT+DDP(TP)方案化疗2个周期以上,评价疗效及不良反应。结果:TC和TP两组近期疗效比较无统计学差异。TP较TC不良反应明显,组间有统计学差异。结论:TC和TP均是治疗蒽环类耐药晚期乳腺癌的有效方案,TC更适合于体质状态稍差的老年患者。
Objective: To observe the short-term efficacy and side effects of docetaxel (TXT) combined with capecitabine (CAP) and cisplatin (DDP) in the treatment of anthracycline-resistant advanced breast cancer. Methods: Eighty - nine patients were randomized to receive TXT + CAP (TC) or TXT + DDP (TP) chemotherapy for more than 2 cycles to evaluate the efficacy and adverse reactions. Results: There was no significant difference in short-term curative effect between TC and TP groups. TP than TC adverse reactions, significant differences between groups. Conclusion: Both TC and TP are effective regimens for the treatment of advanced anthracycline-resistant breast cancer. TC is more suitable for senile patients with slightly worse constitutional status.